All Trials

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with documented colorectal cancer and cancer cachexia per Fearon criteria, excluding those with reversible causes of decreased food intake or on tube/parenteral nutrition. Participants are randomized to subcutaneous NGM120, a GFRAL antagonist monoclonal antibody that inhibits GDF15 signaling, or placebo.

ClinicalTrials.gov ID: NCT07033026

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with extensive-stage SCLC who have relapsed after exactly one prior platinum-based regimen (ECOG 0–1, measurable disease, no active/untreated CNS disease) are randomized to ifinatamab deruxtecan, a B7-H3–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor, versus physician’s choice (topotecan, lurbinectedin, or amrubicin). Key exclusions include prior B7-H3 therapy, prior topoisomerase I inhibitor, ILD/pneumonitis, significant cardiac or corneal disease.

ClinicalTrials.gov ID: NCT06203210

A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral alisertib, a selective Aurora A kinase inhibitor, as monotherapy for adults with ES-SCLC who progressed after platinum plus anti–PD-L1 (≤2 prior lines total). Patients receive alisertib 50–60 mg BID on days 1–7 of 21-day cycles; efficacy will be assessed overall and in predefined biomarker subgroups.

ClinicalTrials.gov ID: NCT06095505

A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Untreated adults with extensive-stage SCLC (measurable extracranial disease, good performance status) are randomized to carboplatin/etoposide plus a fixed-dose of BMS-986489 (BMS-986012, an afucosylated anti–fucosyl-GM1 IgG1 enhancing ADCC/CDC/ADCP, combined with the PD-1 inhibitor nivolumab) versus standard carboplatin/etoposide plus the PD-L1 inhibitor atezolizumab. Primary endpoint is overall survival, with key exclusions including prior ES-SCLC therapy, unstable CNS disease, significant cardiopulmonary disease, active autoimmune disease requiring immunosuppression, and significant neuropathy.

ClinicalTrials.gov ID: NCT06646276

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with HR-positive, HER2-negative locally advanced/metastatic breast cancer after progression on a CDK4/6 inhibitor (no known PIK3CA/AKT1/PTEN alterations; ≤2 prior metastatic lines; no prior chemo/ADC in metastatic setting) are randomized to PF-07248144, a selective KAT6A/6B histone acetyltransferase inhibitor, plus fulvestrant versus everolimus plus endocrine therapy (exemestane or fulvestrant). Assesses progression-free survival, with key secondaries including OS and response; eligibility includes measurable or bone-only disease and ECOG 0–1.

ClinicalTrials.gov ID: NCT07062965

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with HR+/HER2− locally advanced/metastatic breast cancer harboring a primary oncogenic PIK3CA mutation after progression on a CDK4/6 inhibitor and endocrine therapy are randomized to fulvestrant plus RLY-2608—an investigational, allosteric, mutant-selective PI3Kα inhibitor—versus fulvestrant plus capivasertib (AKT inhibitor). Excludes prior PI3K/AKT/mTOR therapy, uncontrolled diabetes, significant CV disease, and tumors with activating AKT or PTEN loss.

ClinicalTrials.gov ID: NCT06982521

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with HR+/HER2- unresectable locally advanced or metastatic breast cancer with measurable disease and progression after prior CDK4/6 inhibitor plus endocrine therapy are randomized to patritumab deruxtecan (HER3-targeted topoisomerase I antibody-drug conjugate) versus physician’s choice chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, liposomal doxorubicin) or trastuzumab deruxtecan. Key exclusions include candidates for further endocrine therapy or PARP inhibitor (gBRCA+), visceral crisis, prior chemo for advanced disease, prior anti-HER3 or topo I ADCs, and active ILD/pneumonitis.

ClinicalTrials.gov ID: NCT07060807

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic colorectal adenocarcinoma, grouped into three cohorts: dMMR/MSI-H refractory to prior PD-1/PD-L1 ± CTLA-4, pMMR/MSS with active non-bulky liver metastases, or pMMR/MSS without liver metastases (cohorts 2–3 post–fluoropyrimidine/oxaliplatin/irinotecan), receive ivonescimab monotherapy. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF to relieve immune suppression and inhibit angiogenesis; primary endpoint is ORR by iRECIST.

ClinicalTrials.gov ID: NCT06959550

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable pleural mesothelioma (epithelioid or non-epithelioid), ECOG 0–1, are randomized to volrustomig (a bispecific PD-1/CTLA-4 antibody) plus carboplatin/pemetrexed versus investigator’s choice of platinum/pemetrexed (epithelioid) or nivolumab plus ipilimumab (either histology; standard for non-epithelioid). Key exclusions include significant autoimmune disease and uncontrolled infections; primary endpoint is overall survival.

ClinicalTrials.gov ID: NCT06097728

A Single-Arm, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic or unresectable leiomyosarcoma after at least two prior systemic regimens (≤2 prior TKIs), ECOG 0–1, receive oral zanzalintinib (XL092), a multi-kinase inhibitor of VEGFR2, MET, and TAM (TYRO3/AXL/MER), given continuously in 14‑day cycles until progression/toxicity. Key exclusions include prior XL092, significant cardiovascular/bleeding risk, unstable CNS disease, and concurrent oral anticoagulants.

ClinicalTrials.gov ID: NCT06571734